Boehringer Ingelheim was the last man standing among challengers to AbbVie’s patents on immunology blockbuster Humira but has joined the pack and settled its litigation. The German company has agreed to delay the introduction of its Humira (adalimumab) biosimilar Cyltezo until 2023, following the example of Amgen, Merck & Co/Samsung Bioepis, Mylan/Fujifilm and Novartis’ Sandoz unit. AbbVie now has breathing space in the US to try to reduce its over-reliance on Humira, which broug...
READ MORE
|
A small population of brain cells deep in a memory-making region of the brain controls the production of new neurons and may have a role in common brain disorders, according to a study from scientists at the University of North Carolina School of Medicine. The scientists, who published their work in Neuron, showed that "mossy cells" in the hippocampus regulate local stem cells to control their production of new neurons, which is important for normal learning and memory, stress response...
UNIVERSITY OF NORTH CAROLINA HEALTH CARE
READ MORE
|
Deutsche Bank is hopeful of better health of pharma stocks going forward due to easing regulatory concerns as well as actions by the US Food and Drug Administration (FDA). The brokerage remains constructive on stocks with superior earnings growth trajectory and strong execution track record. “We forecast the sector to post an 18% CAGR in FY16- 18 (20% CAGR over FY13-16), led by Sun Pharmaceuticals (32%), Aurobindo Pharma (21%) and Glenmark (45%),” the report said. Its top bets are Aurobindo ...
READ MORE
|
Chasing biosim partners Mylan and Biocon for one of the top sales targets in the pharma industry, Celltrion reported Sunday that its version of Roche’s breast cancer med Herceptin stacked up to the reference blockbuster in a late-stage trial....
READ MORE
|
The Pharmaceutical Services Negotiating Committee PSNC, Department of Health and Social Care DHSC and NHS England have announced a five-year funding framework for community pharmacy. The framework agreement for community pharmacies announced funding of almost 13 billion pounds over the five years to 2023-24, with 2.592 billion pounds per year, for pharmacies. The announcement also states that a new NHS Community Pharmacist Consultation Service CPCS will be introduced nationally as an advanced se...
READ MORE
|
Lawmakers in the nation's capital have yet to grapple with rising drug costs, but Ohio voters are being asked in a single ballot-box question next week to figure out how best to lower the tab the state pays for prescriptions....
READ MORE
|